According to an open-access story at TechCrunch and a subscription article at Business Insider, Alphabet's life sciences arm, Verily, "eliminated its entire medical devices program" this week.
Alphabet has a market cap of about $2 trillion, of which Google Search is about 80% of revenue. Its life sciences businesses (Verily, Calico) are tiny by comparison.
According to a web search by Chat GPT 5, experimental or discontinued projects at Verily included a spoon for tremors (acquied Liftware), a glucose-sensing contact lens, a retinal camera, and miniatured glucose monitors in collaboration with Dexcom.
Absent "devices," Verily life sciences interests could include AI oriented toward digital health startups, pharma, healthcare systems improvements. Lightpath, for example, is an AI-powered chronic care app in development.
##
Past leadership at Verily included Dr Amy Abernethy and Dr Andrew Conrad (now at S32 VC). Stephen Gillett is CEO since 2003; prior positions included Symantec (as COO) and Best Buy.
In mid-2024, Verily announced it was shifting its headquarters to Dallas-Ft. Worth. Nicole Ward at DallasInnovates.com writes,
- Verily, born as a moonshot project at Google X, has consistently pursued ambitious goals in healthcare technology. The company develops advanced tools and solutions to help patients, providers, and researchers navigate the healthcare landscape. Its offerings range from consumer-facing products like diabetes management apps and retinal screening devices to sophisticated data analytics platforms for healthcare professionals.
- Since establishing its Dallas office, Verily has rapidly emerged as a force in Dallas-Fort Worth’s growing healthcare and tech ecosystem.
##
